Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Grp78 as a therapeutic target for refractory head–neck cancer with CD24−CD44+ stemness phenotype

Cancer Gene Therapy volume 20, pages 606–615 (2013)Cite this article

Subjects

Abstract

Cancer stem cells are refractory to conventional therapy, which result to cancer metastasis and chemo-radioresistance. Grp78 is known to have important roles in cytoprotection and tumorigenesis in several cancers. We therefore examined whether Grp78 can serve as a therapeutic target for refractory stemness phenotype of head and neck cancer (HNC). Six HNC cell lines were used. Fluorescence-activated cell sorting (FACS) analysis was used to sort CD24−CD44+ and Grp78+ cells. The small interfering RNA (siRNA) knockdown and cDNA transfection were applied to examine the effects of Grp78 on cellular function. Western blot and confocol microscopy were used to determine the effects of downstream protein expressions. Xenografted mouse tumors and immunohistochemistry were used to validate the results. We found that Grp78 regulated the conversion of CD24−CD44+ cells, a characteristic of HNC stem cells. The CD24−CD44+Grp78+ cells showed superior chemo-radioresistance and invasion ability compared with CD24−CD44+, Grp78+ or the parental cells. Silencing Grp78 increased chemo-radiosensitivity, inhibited cell invasion, reverse epithelial–mesenchymal transition, suppressed cancer stemness, withdrew CD24−CD44+ cell conversion and induced differentiated phenotype. Study in xenografted mice further showed that CD24−CD44+Grp78+ cells exhibited highest tumorigenesis, compared with CD24−CD44+ CD24+CD44+ or the parental cells. Grp78 knockdown dramatically restrained tumor growth along with the inhibition of stem cell regulatory proteins Oct-4 and Slug. Grp78 may serve as a molecular target that can be further developed for eradication of refractory HNC with stemness phenotype.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309–316.

    Article  Google Scholar 

  2. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008; 99: 1507–1514.

    Article  CAS  Google Scholar 

  3. Stucken E, Weissman J, Spiegel JH . Oral cavity risk factors: experts' opinions and literature support. J Otolaryngol Head Neck Surg 2010; 39: 76–89.

    PubMed  Google Scholar 

  4. Saman DM . A review of the epidemiology of oral and pharyngeal carcinoma: update. Head Neck Oncol 2012; 4: 1.

    Article  Google Scholar 

  5. Keysar SB, Jimeno A . More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010; 9: 2450–2457.

    Article  CAS  Google Scholar 

  6. O'Brien CA, Kreso A, Jamieson CH . Cancer stem cells and self-renewal. Clin Cancer Res 2010; 16: 3113–3120.

    Article  CAS  Google Scholar 

  7. Sugihara E, Saya H . Complexity of cancer stem cells. Int J Cancer 2013; 132: 1249–1259.

    Article  CAS  Google Scholar 

  8. Alison MR, Lin WR, Lim SM, Nicholson LJ . Cancer stem cells: in the line of fire. Cancer Treat Rev 2012; 38: 589–598.

    Article  CAS  Google Scholar 

  9. Sampieri K, Fodde R . Cancer stem cells and metastasis. Semin Cancer Biol 2012; 22: 187–193.

    Article  CAS  Google Scholar 

  10. Grotenhuis BA, Wijnhoven BP, van Lanschot JJ . Cancer stem cells and their potential implications for the treatment of solid tumors. J Surg Oncol 2012; 106: 209–215.

    Article  CAS  Google Scholar 

  11. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 2011; 117: 162–174.

    Article  Google Scholar 

  12. Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y et al. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res 2011; 31: 495–500.

    CAS  PubMed  Google Scholar 

  13. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013; 229: 355–378.

    Article  CAS  Google Scholar 

  14. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973–978.

    Article  CAS  Google Scholar 

  15. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PloS ONE 2011; 6: e16466.

    Article  CAS  Google Scholar 

  16. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL . CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Brit J Cancer 2008; 98: 756–765.

    Article  CAS  Google Scholar 

  17. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr., Badve S et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 2010; 10: 411.

    Article  CAS  Google Scholar 

  18. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 2012; 29: 939–948.

    Article  CAS  Google Scholar 

  19. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43: 364–373.

    Article  CAS  Google Scholar 

  20. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A . Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013; 13: 7–15.

    Article  CAS  Google Scholar 

  21. Li J, Lee AS . Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2016; 6: 45–54.

    Article  Google Scholar 

  22. Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008; 6: 1268–1275.

    Article  CAS  Google Scholar 

  23. Luo S, Mao C, Lee B, Lee AS . GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 2006; 26: 5688–5697.

    Article  CAS  Google Scholar 

  24. Chiu CC, Lin CY, Lee LY, Chen YJ, Kuo TF, Chang JT et al. Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention. Mol Cancer Ther 2008; 7: 2788–2797.

    Article  CAS  Google Scholar 

  25. Quinones QJ, de Ridder GG, Pizzo SV . GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum. Histol Histopathol 2008; 23: 1409–1416.

    CAS  PubMed  Google Scholar 

  26. Ni M, Zhang Y, Lee AS . Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434: 181–188.

    Article  CAS  Google Scholar 

  27. Chen YJ, Chang JT, Lee L, Wang HM, Liao CT, Chiu CC et al. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 2007; 26: 467–476.

    Article  CAS  Google Scholar 

  28. Chang JT, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007; 6: 2271–2279.

    Article  CAS  Google Scholar 

  29. Chiu CC, Lin CY, Lee LY, Chen YJ, Lu YC, Wang HM et al. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res 2011; 17: 4629–4641.

    Article  CAS  Google Scholar 

  30. Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH et al. Downregulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. Head Neck 2011; 33: 257–266.

    Article  Google Scholar 

  31. Lin TY, Chang JT, Wang HM, Chan SH, Chiu CC, Lin CY et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 246–256.

    Article  CAS  Google Scholar 

  32. Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY et al. Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Cancer Lett 2009; 284: 131–140.

    Article  CAS  Google Scholar 

  33. Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, Wang HM et al. Positive association of glucose-regulated protein 78 during oral cancer progression and the prognostic value in oral precancerous lesions. Head Neck 2010; 32: 1028–1039.

    Article  Google Scholar 

  34. Tiwari N, Gheldof A, Tatari M, Christofori G . EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012; 22: 194–207.

    Article  CAS  Google Scholar 

  35. Biddle A, Mackenzie IC . Cancer stem cells and EMT in carcinoma. Cancer Meta Rev 2012; 31: 285–293.

    Article  Google Scholar 

  36. White CD, Brown MD, Sacks DB . IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009; 583: 1817–1824.

    Article  CAS  Google Scholar 

  37. Sugiura K, Muro Y, Futamura K, Matsumoto K, Hashimoto N, Nishizawa Y et al. The unfolded protein response is activated in differentiating epidermal keratinocytes. J Invest Dermatol 2009; 129: 2126–2135.

    Article  CAS  Google Scholar 

  38. Pei D . Regulation of pluripotency and reprogramming by transcription factors. J Biol Chem 2009; 284: 3365–3369.

    Article  CAS  Google Scholar 

  39. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Chen B et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg 2011; 253: 1165–1171.

    Article  Google Scholar 

  40. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY . Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40: 621–628.

    Article  CAS  Google Scholar 

  41. Siu A, Lee C, Dang D, Ramos DM . Stem cell markers as predictors of oral cancer invasion. Anticancer Res 2012; 32: 1163–1166.

    CAS  PubMed  Google Scholar 

  42. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059–2068.

    Article  CAS  Google Scholar 

  43. Shih JY, Yang PC . The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011; 32: 1299–1304.

    Article  CAS  Google Scholar 

  44. Matsuda Y, Kure S, Ishiwata T . Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 2012; 45: 59–65.

    Article  CAS  Google Scholar 

  45. Jang S, Yang TH, An EJ, Yoon HK, Sohn KC, Cho AY et al. Role of plasminogen activator inhibitor-2 (PAI-2) in keratinocyte differentiation. J Dermatol Sci 2010; 59: 25–30.

    Article  CAS  Google Scholar 

  46. Begum S, Joshi M, Ek M, Holgersson J, Kleman MI, Sumitran-Holgersson S . Characterization and engraftment of long-term serum-free human fetal liver cell cultures. Cytotherapy 2010; 12: 201–211.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Chang Gung Memorial Hospital (CMRPD1A0642 and CMRPG190393) and from the Department of Health of Taiwan (DOH99-TD-C-111-006).

Author information

Authors and Affiliations

  1. Department of Medical Biotechnology, College of Medicine, Chang Gung University, Taoyuan, Taiwan

    C-C Chiu, Y-C Li, Y-J Chen, Y-C Lu, Y-L Li & A-J Cheng

  2. Department of Pathology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan

    L-Y Lee

  3. Department of Medical Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan

    H-M Wang

  4. Department of Radiation Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan

    J T Chang

Authors
  1. C-C Chiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L-Y Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y-C Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y-C Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-L Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H-M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J T Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A-J Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A-J Cheng.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiu, CC., Lee, LY., Li, YC. et al. Grp78 as a therapeutic target for refractory head–neck cancer with CD24−CD44+ stemness phenotype. Cancer Gene Ther 20, 606–615 (2013). https://doi.org/10.1038/cgt.2013.64

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2013.64

Keywords

This article is cited by

Search

Advanced search

Quick links